Non-Alcoholic Fatty Liver Disease

AlHadyan, Roula Hadyan Mohammed; Khojah, Albader Abdulhameed Y; AbdullahAlanazi, Abdulaziz Ghareeb; Alharbi, Ahmed Nasser A; Al-Zubaidi, Saeed Aqeel S; Traboulsi, Ziad Khodr; Alasseri, IbrahimAli I.; Algarni, Ahmad Yeanallah; Al-Mubarak, Hassan Ali A; Alzahrani, Ahmed Abdullah Y; Al Saeed, Bashaier Abdalrazaq; Alruwaili, Hamoud Jadan M

doi:10.12816/0043808

Non-Alcoholic Fatty Liver Disease

Document Type : Original Article

Authors

¹ Al-Maarefa Collages

² King Fahd General Hospital Jeddah

³ Najran University

⁴ Qassim University

⁵ Batterjee Medical College

⁶ King Abdulaziz University

⁷ Majardah General Hospital, MROD

⁸ Imam Abdulrahman Bin Faisal University

⁹ University of Jeddah

¹⁰ Ibn Sina National College

¹¹ Aljouf University

10.12816/0043808

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease that exposes patients to a great risk of emerging cardiovascular diseases and could develop to cirrhosis or hepatocellular carcinoma if left unmanaged.
Objective of the Study: this article is intended to provide an overview and explore the optimal intervention for management of NAFLD in the short and long term.
Methods: Electronic search in the scientific database from 1966 to 2017– (Medline, Embase, the Cochrane Library as well as NHS center websites were searched for English Publications were obtained from both reprint requests and by searching the database. Data extracted included authors, country, year of publication, age and sex of patients, epidemiology, geographical distribution, pathophysiology, risk factors, clinical manifestations, investigations and types of surgical treatment.
Conclusion: It was concluded from the extensive review of the literature that Lifestyle modification including diet, physical activity and controlling metabolic disorders are the cornerstone in current management of NAFLD. Nevertheless, Insulin-sensitizing agents and antioxidants, particularly thiazolidinediones and vitamin E, seem to be a very promising pharmacologic treatment for non-alcoholic steatohepatitis, yet further long-term multicenter studies need to be conducted for confirmation and assessment.

Keywords